TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced that it is scheduled to participate in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9–10, 2026, in New York City.
Yoram Drucker, Co-Founder, Chairman and Vice President of Strategic Development of NurExone, will deliver an investor presentation and participate in scheduled one-on-one meetings with investors. “As NurExone continues its preclinical development activities and preparations for potential clinical development, we are also taking steps intended to support the manufacturing and commercial capabilities that may be required for the Company’s longer-term development,” said Mr. Drucker. “We look forward to participating in the Moody Capital Solutions conference and engaging with members of the investment community. The conference will provide an opportunity to discuss the Company’s therapeutic-development activities, exosome platform and U.S. manufacturing and commercial initiatives with members of the investment community.”